Mike Reddy for STAT

STAT+ | Not just Rogaine: Biotech investors see promise in a new wave of hair loss treatments

Pelage Pharmaceuticals and Veradermics raise a combined $270 million to develop treatments for hair loss, a field long dominated by "lotions and potions."

By Allison DeAngelis

STAT+ | Trump announces deal with Lilly, Novo to expand access to weight loss drugs, cut prices

Novo Nordisk's Wegovy, Eli Lilly's Zepbound to be sold at discounted prices on TrumpRx, covered by Medicare under new Trump deal.

By Daniel Payne and Elaine Chen

STAT+ | FDA announces next round of priority review vouchers

Process speeds up FDA approval for drugs that reflect Trump priorities. Watchdogs say program may hand out political favors more than advance public health

By Lizzy Lawrence

Arthur Chien/ Science Photo Library

As brain organoids grow increasingly complex, leading scientists and bioethicists call for global oversight

As neural organoids grow more complex, scientists and ethicists urge oversight of research with these 3D structures made from human cells

By Megan Molteni

STAT+ | Mark Cuban is trying to shake up biosimilar pricing with a version of J&J’s best-selling Stelara drug

The Mark Cuban Cost Plus Drug Company will sell a cheaper version of Stelara, a J&J treatment used for chronic inflammatory and autoimmune conditions.

By Ed Silverman and Elaine Chen

STAT+ | The FDA is a mess, but don’t blame it for everything 

In this week's edition of Adam's Biotech Scorecard, Adam looks at Biohaven Pharmaceuticals and Uniqure and whether FDA turmoil explains their setbacks.

By Adam Feuerstein

Adobe

Opinion: How Congress can still get health care subsidies in place for 2026

Late action after the government reopens could still make a real difference for American families’ wallets and lives, experts writes.

By Emily Gee